Navigation Links
Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
Date:11/27/2007

MENLO PARK, Calif., Nov. 27 /PRNewswire/ -- Corium International, Inc., a privately-held transdermal drug delivery company, today announced the appointment of Phyllis Gardner, M.D. and Daniel G. Welch to the Board of Directors. Dr. Gardner, an adjunct partner at Essex Woodlands Health Ventures, is a Professor of Medicine at Stanford University and widely published in the fields of cell biology and pharmacology. In addition to her academic work, Dr. Gardner has been active in the biotechnology and pharmaceutical industries. In 1996, she took a leave of absence from Stanford and joined ALZA Corporation as a Principal Scientist, Vice President of Research, and Head of the ALZA Technology Institute. Dr. Gardner is the co-founder of Genomics Collaborative, Inc. (now a division of Bioserve), SKOLAR MD (acquired by Wolters Klure) and APEX DX, LLC. She currently serves on the boards of Ventaira Pharmaceuticals, UMD, Inc., and Revance, Inc., and she is on the Scientific Advisory Board of Aradigm Corp. Dr. Gardner received her M.D. from Harvard Medical School, and received postgraduate training at Massachusetts General Hospital, Stanford School of Medicine, Columbia University and University College London.

Daniel G. Welch has served as Chief Executive Officer and President of InterMune since September 2003. Prior to InterMune, Mr. Welch was Chairman and CEO of Triangle Pharmaceuticals, a biopharmaceutical company, which was acquired by Gilead. From 2000 to 2002, he was President of Biopharmaceuticals at Elan Corporation where he was responsible for U.S. commercial operations, the international subsidiaries, the R&D function and the diagnostics businesses. Mr. Welch served in several senior management roles at Sanofi-Aventis during the years 1987 to 2000, including Vice President of Worldwide Marketing and COO of the U.S. business. Prior to joining Sanofi-Aventis, Mr. Welch was with American Critical Care, a division of American Hospital Supply. Mr. Welch is a member of the Board of Directors of Seattle Genetics, Inc. and BayBio, the bay-area biotech industry association. He holds an M.B.A. from the University of North Carolina and a B.B.A. from the University of Miami.

Dr. Gardner and Mr. Welch join current Corium board members John Kozarich, Chairman and President, ActivX Biosciences, Inc., Ron Eastman, Chairman of the Board and Partner at Essex Woodlands Health Ventures, Robert Thomas, CEO of Corium and former FoxHollow Technologies CEO, Gary Cleary, co-founder of Corium and CTO, and Ravi Srinivasan, co-founder of Stratagent Life Sciences and VP of Engineering at Corium. The Company recently completed a $25.1 million Series C financing led by Essex Woodlands Health Ventures. Corium is using the proceeds to continue the development and commercialization of a pipeline of advanced transdermal products employing its proprietary MicroCor(TM) microneedle technology, Corplex(TM) polymer adhesive technology, and MicroJet liquid drug delivery technology.

Corium is headquartered in Menlo Park, CA, with manufacturing facilities in Grand Rapids, MI.

About Corium International, Inc.

Corium International, Inc. is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development. Please visit http://www.coriumgroup.com

About Essex Woodlands Health Ventures

With $1.6 billion under management, Essex Woodlands is one of the nation's largest and oldest venture capital firms pursuing investments in pharmaceuticals, biotechnology, medical devices, health services, managed care and health information. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of over 100 healthcare companies ranging across all sectors, stages and geography, and brings over 240 years of collective healthcare experience. The team is comprised of 23 professionals with principal offices in Palo Alto, California, Houston, Texas, New York City and London. For more information, please see http://www.ewhv.com.

Contact: Corium International, Inc.

Christina Dickerson

Director, Corporate Development

650.298.8257

christina@coriumtech.com


'/>"/>
SOURCE Corium International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
2. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface ... detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
Breaking Biology News(10 mins):